1. Home
  2. IMCR vs PLPC Comparison

IMCR vs PLPC Comparison

Compare IMCR & PLPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$28.63

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Preformed Line Products Company

PLPC

Preformed Line Products Company

HOLD

Current Price

$380.40

Market Cap

1.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCR
PLPC
Founded
2008
1947
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Water Sewer Pipeline Comm & Power Line Construction
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
2016
2001

Fundamental Metrics

Financial Performance
Metric
IMCR
PLPC
Price
$28.63
$380.40
Analyst Decision
Buy
Strong Buy
Analyst Count
10
1
Target Price
$66.33
$275.00
AVG Volume (30 Days)
304.3K
100.6K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
0.25%
EPS Growth
30.39
N/A
EPS
0.25
2.14
Revenue
$249,428,000.00
N/A
Revenue This Year
$14.57
$17.19
Revenue Next Year
$8.21
$7.28
P/E Ratio
$117.72
$176.46
Revenue Growth
43.05
N/A
52 Week Low
$27.56
$138.93
52 Week High
$40.71
$377.89

Technical Indicators

Market Signals
Indicator
IMCR
PLPC
Relative Strength Index (RSI) 44.87 64.73
Support Level $27.69 $298.40
Resistance Level $31.56 N/A
Average True Range (ATR) 1.14 16.77
MACD 0.08 1.30
Stochastic Oscillator 22.02 91.18

Price Performance

Historical Comparison
IMCR
PLPC

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About PLPC Preformed Line Products Company

Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. The Company's primary products support, protect, connect, terminate, and secure cables and wires. The Company provides helical solutions, connectors, fiber optic and copper splice closures, solar framing applications, and electric vehicle charging station foundations. The Company's customers include public and private energy utilities and communication companies, cable operators, contractors and subcontractors, distributors, and value-added resellers. Geographically, the company operates in four regions: PLP-USA, the Americas, EMEA, and Asia-Pacific.

Share on Social Networks: